1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Aggregatibacter	_	_	NNP	_	_	_	_	_
2	actinomycetemcomitans	_	_	NNS	_	_	_	_	_


1	is	_	_	VBZ	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	Gram-negative	_	_	JJ	_	_	_	_	_
4	member	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	human	_	_	JJ	_	_	_	_	_
8	oral	_	_	JJ	_	_	_	_	_
9	microbiota	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	involved	_	_	VBN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	human	_	_	JJ	_	_	_	_	_
15	infections	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	diseases	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	diseases	_	_	NNS	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	periodontitis	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	characterized	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	destruction	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	tooth-supporting	_	_	JJ	_	_	_	_	_
13	periodontal	_	_	JJ	_	_	_	_	_
14	tissues	_	_	NNS	_	_	_	_	_
15	due	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	inflammatory	_	_	JJ	_	_	_	_	_
19	response	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	A.	_	_	FW	_	_	_	_	_
2	actinomycetemcomitans	_	_	FW	_	_	_	_	_


1	possesses	_	_	VBZ	_	_	_	_	_
2	several	_	_	JJ	_	_	_	_	_
3	virulence	_	_	NN	_	_	_	_	_
4	factors	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	which	_	_	WDT	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	production	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	RTX	_	_	NNP	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	repeats-in-toxin	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	leukotoxin	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	LtxA	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	has	_	_	VBZ	_	_	_	_	_
21	received	_	_	VBN	_	_	_	_	_
22	much	_	_	JJ	_	_	_	_	_
23	attention	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	LtxA	_	_	NNP	_	_	_	_	_
2	induces	_	_	VBZ	_	_	_	_	_
3	cell	_	_	NN	_	_	_	_	_
4	lysis	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	degranulation	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	inflammatory	_	_	JJ	_	_	_	_	_
10	response	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	human	_	_	JJ	_	_	_	_	_
13	leukocytes	_	_	NNS	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	interaction	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	β2-integrins	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	cell	_	_	NN	_	_	_	_	_
22	membrane	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	human	_	_	JJ	_	_	_	_	_
25	immune	_	_	JJ	_	_	_	_	_
26	cells	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	530-bp	_	_	CD	_	_	_	_	_
3	deletion	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	promoter	_	_	NN	_	_	_	_	_
7	region	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	LtxA	_	_	NNP	_	_	_	_	_
11	gene	_	_	NN	_	_	_	_	_
12	operon	_	_	NN	_	_	_	_	_
13	was	_	_	VBD	_	_	_	_	_
14	identified	_	_	VBN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	original	_	_	JJ	_	_	_	_	_
18	JP2	_	_	NNP	_	_	_	_	_
19	strain	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	cultured	_	_	VBN	_	_	_	_	_
22	from	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	young	_	_	JJ	_	_	_	_	_
25	individual	_	_	NN	_	_	_	_	_
26	diagnosed	_	_	VBN	_	_	_	_	_
27	with	_	_	IN	_	_	_	_	_
28	juvenile	_	_	JJ	_	_	_	_	_
29	periodontitis	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	discovery	_	_	NN	_	_	_	_	_
3	marked	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	beginning	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	era	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	where	_	_	WRB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	detection	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	530-bp	_	_	CD	_	_	_	_	_
16	deletion	_	_	NN	_	_	_	_	_
17	categorized	_	_	VBD	_	_	_	_	_
18	highly	_	_	RB	_	_	_	_	_
19	leukotoxic	_	_	JJ	_	_	_	_	_
20	A.	_	_	NNP	_	_	_	_	_
21	actinomycetemcomitans	_	_	NNS	_	_	_	_	_
22	strains	_	_	NNS	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	member	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	JP2	_	_	NNP	_	_	_	_	_
29	clone	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	A.	_	_	NNP	_	_	_	_	_
32	actinomycetemcomitans	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	possessing	_	_	VBG	_	_	_	_	_
35	enhanced	_	_	VBN	_	_	_	_	_
36	virulence	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Based	_	_	VBN	_	_	_	_	_
2	on	_	_	IN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	vitro	_	_	NN	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	it	_	_	PRP	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	reported	_	_	VBN	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	JP2	_	_	NNP	_	_	_	_	_
13	genotype	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	A.	_	_	NNP	_	_	_	_	_
16	actinomycetemcomitans	_	_	NN	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	10	_	_	CD	_	_	_	_	_
20	–	_	_	TO	_	_	_	_	_
21	20	_	_	CD	_	_	_	_	_
22	fold	_	_	NN	_	_	_	_	_
23	higher	_	_	JJR	_	_	_	_	_
24	lytic	_	_	NN	_	_	_	_	_
25	activity	_	_	NN	_	_	_	_	_
26	than	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	non-JP2	_	_	NN	_	_	_	_	_
29	genotypes	_	_	NNS	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	A.	_	_	NNP	_	_	_	_	_
32	actinomycetemcomitans	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	longitudinal	_	_	JJ	_	_	_	_	_
4	clinical	_	_	JJ	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	reported	_	_	VBD	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	clear	_	_	JJ	_	_	_	_	_
9	correlation	_	_	NN	_	_	_	_	_
10	between	_	_	IN	_	_	_	_	_
11	being	_	_	VBG	_	_	_	_	_
12	carrier	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	JP2	_	_	NNP	_	_	_	_	_
16	genotype	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	A.	_	_	NNP	_	_	_	_	_
19	actinomycetemcomitans	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	having	_	_	VBG	_	_	_	_	_
22	an	_	_	DT	_	_	_	_	_
23	increased	_	_	VBN	_	_	_	_	_
24	risk	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	developing	_	_	VBG	_	_	_	_	_
27	periodontitis	_	_	NN	_	_	_	_	_
28	at	_	_	IN	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	young	_	_	JJ	_	_	_	_	_
31	age	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Often	_	_	RB	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	leukotoxic	_	_	JJ	_	_	_	_	_
4	potential	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	A.	_	_	NNP	_	_	_	_	_
7	actinomycetemcomitans	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	characterized	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	leukotoxicity	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	in	_	_	FW	_	_	_	_	_
15	vitro	_	_	NN	_	_	_	_	_
16	studies	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	leukotoxicity	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	determined	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	use	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	cell	_	_	NN	_	_	_	_	_
9	lysis	_	_	NN	_	_	_	_	_
10	assays	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	where	_	_	WRB	_	_	_	_	_
13	human	_	_	JJ	_	_	_	_	_
14	immune	_	_	JJ	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	exposed	_	_	VBN	_	_	_	_	_
18	either	_	_	CC	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	bacteria	_	_	NN	_	_	_	_	_
22	or	_	_	CC	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	purified	_	_	VBN	_	_	_	_	_
25	LtxA	_	_	NNP	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	most	_	_	RBS	_	_	_	_	_
29	often	_	_	RB	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	leukotoxicity	_	_	NN	_	_	_	_	_
32	is	_	_	VBZ	_	_	_	_	_
33	correlated	_	_	VBN	_	_	_	_	_
34	with	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	JP2	_	_	NN	_	_	_	_	_
37	or	_	_	CC	_	_	_	_	_
38	non-JP2	_	_	NN	_	_	_	_	_
39	genotype	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	A.	_	_	NNP	_	_	_	_	_
43	actinomycetemcomitans	_	_	NN	_	_	_	_	_
44	strain	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	common	_	_	JJ	_	_	_	_	_
8	believe	_	_	VBP	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	leukotoxicity	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	an	_	_	DT	_	_	_	_	_
14	A.	_	_	NNP	_	_	_	_	_
15	actinomycetemcomitans	_	_	NN	_	_	_	_	_
16	strain	_	_	NN	_	_	_	_	_
17	could	_	_	MD	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	explained	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	530-bp	_	_	CD	_	_	_	_	_
23	deletion	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	an	_	_	DT	_	_	_	_	_
26	explanation	_	_	NN	_	_	_	_	_
27	supported	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	recent	_	_	JJ	_	_	_	_	_
30	results	_	_	NNS	_	_	_	_	_
31	presented	_	_	VBN	_	_	_	_	_
32	by	_	_	IN	_	_	_	_	_
33	Sampathkumar	_	_	NNP	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	co-workers	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	A.	_	_	NNP	_	_	_	_	_
4	actinomycetemcomitans	_	_	NN	_	_	_	_	_
5	strains	_	_	NNS	_	_	_	_	_
6	without	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	530-bp	_	_	CD	_	_	_	_	_
9	deletion	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	high	_	_	JJ	_	_	_	_	_
12	leukotoxicity	_	_	NN	_	_	_	_	_
13	according	_	_	VBG	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	results	_	_	NNS	_	_	_	_	_
16	obtained	_	_	VBN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	cell	_	_	NN	_	_	_	_	_
19	lysis	_	_	NN	_	_	_	_	_
20	assay	_	_	NN	_	_	_	_	_
21	have	_	_	VBP	_	_	_	_	_
22	been	_	_	VBN	_	_	_	_	_
23	reported	_	_	VBN	_	_	_	_	_
24	on	_	_	IN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	leukotoxic	_	_	JJ	_	_	_	_	_
5	potential	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	A.	_	_	NNP	_	_	_	_	_
8	actinomycetemcomitans	_	_	NNS	_	_	_	_	_
9	strains	_	_	NNS	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	explained	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	different	_	_	JJ	_	_	_	_	_
15	mechanisms	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	higher	_	_	JJR	_	_	_	_	_
3	expression	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	mRNA	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	encoding	_	_	VBG	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	ltxA	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	has	_	_	VBZ	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	reported	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	correspond	_	_	VB	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	higher	_	_	JJR	_	_	_	_	_
20	leukotoxic	_	_	JJ	_	_	_	_	_
21	potential	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	but	_	_	CC	_	_	_	_	_
24	also	_	_	RB	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	variation	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	activity	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	LtxA	_	_	NNP	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	some	_	_	DT	_	_	_	_	_
34	A.	_	_	NNP	_	_	_	_	_
35	actinomycetemcomitans	_	_	NNS	_	_	_	_	_
36	has	_	_	VBZ	_	_	_	_	_
37	been	_	_	VBN	_	_	_	_	_
38	reported	_	_	VBN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Only	_	_	RB	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	few	_	_	JJ	_	_	_	_	_
4	studies	_	_	NNS	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	compared	_	_	VBN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	leukotoxicity	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	A.	_	_	NNP	_	_	_	_	_
11	actinomycetemcomitans	_	_	NN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	LtxA	_	_	NNP	_	_	_	_	_
15	expression	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	production	_	_	NN	_	_	_	_	_
18	defined	_	_	VBN	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	quantification	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	LtxA	_	_	NNP	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	e.	_	_	FW	_	_	_	_	_
27	g.	_	_	FW	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	enzyme-linked	_	_	JJ	_	_	_	_	_
31	immunosorbent	_	_	NN	_	_	_	_	_
32	assay	_	_	NN	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	ELISA	_	_	NNP	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	or	_	_	CC	_	_	_	_	_
38	mRNA	_	_	NN	_	_	_	_	_
39	coding	_	_	VBG	_	_	_	_	_
40	for	_	_	IN	_	_	_	_	_
41	LtxA	_	_	NNP	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	but	_	_	CC	_	_	_	_	_
44	it	_	_	PRP	_	_	_	_	_
45	seems	_	_	VBZ	_	_	_	_	_
46	reasonable	_	_	JJ	_	_	_	_	_
47	to	_	_	TO	_	_	_	_	_
48	assume	_	_	VB	_	_	_	_	_
49	that	_	_	IN	_	_	_	_	_
50	the	_	_	DT	_	_	_	_	_
51	two	_	_	CD	_	_	_	_	_
52	factors	_	_	NNS	_	_	_	_	_
53	are	_	_	VBP	_	_	_	_	_
54	related	_	_	VBN	_	_	_	_	_
55	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	aimed	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	investigate	_	_	VB	_	_	_	_	_
10	if	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	leukotoxicity	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	collection	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	Ghanaian	_	_	JJ	_	_	_	_	_
18	A.	_	_	NNP	_	_	_	_	_
19	actinomycetemcomitans	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	serotype	_	_	NN	_	_	_	_	_
22	b	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	is	_	_	VBZ	_	_	_	_	_
25	related	_	_	VBN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	LtxA	_	_	NNP	_	_	_	_	_
29	production	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	strains	_	_	NNS	_	_	_	_	_
33	determined	_	_	VBN	_	_	_	_	_
34	by	_	_	IN	_	_	_	_	_
35	Western	_	_	JJ	_	_	_	_	_
36	blotting	_	_	NN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	ELISA	_	_	NNP	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	LtxA	_	_	NNP	_	_	_	_	_
42	expression	_	_	NN	_	_	_	_	_
43	as	_	_	IN	_	_	_	_	_
44	determined	_	_	VBN	_	_	_	_	_
45	in	_	_	IN	_	_	_	_	_
46	a	_	_	DT	_	_	_	_	_
47	mRNA	_	_	NN	_	_	_	_	_
48	expression	_	_	NN	_	_	_	_	_
49	assay	_	_	NN	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	wanted	_	_	VBD	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	compare	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	results	_	_	NNS	_	_	_	_	_
9	obtained	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	ELISA	_	_	NNP	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	mRNA	_	_	NN	_	_	_	_	_
14	expression	_	_	NN	_	_	_	_	_
15	assay	_	_	NN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	elucidate	_	_	VB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	relationship	_	_	NN	_	_	_	_	_
20	between	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	two	_	_	CD	_	_	_	_	_
23	quantification	_	_	NN	_	_	_	_	_
24	methods	_	_	NNS	_	_	_	_	_
25	used	_	_	VBN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	determine	_	_	VB	_	_	_	_	_
28	leukotoxic	_	_	JJ	_	_	_	_	_
29	potential	_	_	NN	_	_	_	_	_
30	as	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	LtxA	_	_	NNP	_	_	_	_	_
33	production	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	expression	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	A.	_	_	NN	_	_	_	_	_
38	actinomycetemcomitans	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	respectively	_	_	RB	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_

